Jeffrey B. Landau - 19 Jul 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Issuer symbol
CTMX
Transactions as of
19 Jul 2022
Net transactions value
-$5,982
Form type
4
Filing time
21 Jul 2022, 16:11:13 UTC
Previous filing
28 Mar 2022
Next filing
12 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +11,250 +48% $0.000000 34,931 19 Jul 2022 Direct F1, F2, F3
transaction CTMX Common Stock Sale $5,982 -4,206 -12% $1.42 30,725 20 Jul 2022 Direct F2, F4
holding CTMX Common Stock 4,500 19 Jul 2022 Fidelity Traditional IRA
holding CTMX Common Stock 3,180 19 Jul 2022 Schwab ROTH IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
F2 Includes 16,274 restricted stock units.
F3 Reflects the adjusted total which includes the purchase of 5,040 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
F4 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.